International Journal of Heart Failure.2024;6(4):174-175. doi:10.36628/ijhf.2024.0058
International Journal of Heart Failure
2002 (v1, n1) to Present ISSN: 1671-8925
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
The Next Chapter of International Journal of Heart Failure
International Journal of Heart Failure.2024;6(4):159-160. doi:10.36628/ijhf.2024.0054
Current and Future of Heart Failure Care in Asia
International Journal of Heart Failure.2024;6(4):141-148. doi:10.36628/ijhf.2024.0033
Heart failure (HF) is a significant global health concern, particularly in Asia, where over half of the world's population resides. Despite advances in treatment, the burden of HF is expected to rise in the region due to the aging population and an increase in non-communicable diseases associated with HF risk. This narrative review examines the current state of HF in Asia, highlighting differences in treatment utilization, underrepresentation of Asian individuals in clinical trials, emerging therapies, and implementation strategies, including the potential use of polypills and the need for expanded HF training opportunities for healthcare providers.
International Journal of Heart Failure.2024;6(4):176-178. doi:10.36628/ijhf.2024.0018
Trends of Left Ventricular Assist Device Implantation and Heart Transplantation in Korea
International Journal of Heart Failure.2024;6(4):161-164. doi:10.36628/ijhf.2024.0024
International Journal of Heart Failure.2024;6(4):149-158. doi:10.36628/ijhf.2024.0021
Heart failure (HF) as a syndrome which is normally associated with significant reduction of cardiac output has evolved to include conditions such those of moderate and preserved ejection fraction. While the prevalence of HF in the population is increasing, it is not HF with reduced ejection fraction that is driving the trajectory upward for mortality. There is some evidence to suggest that a better understanding of the pathophysiology, novel pharmacological strategies, devices, as well as remote monitoring of the hemodynamics seem to account for a reduction in the cardiovascular mortality and re-hospitalization in some cohorts with HF. However, the all-cause mortality associated with HF has not been reduced significantly by the current interventions. To explore the potential approaches needed for the strategies and avenues to reduce all-cause mortality in patients with HF, it would be helpful to evaluate the evidence in the literature directed at the care of patients with chronic/acute decompensated HF. It is evident that ambulatory measurements of pressures and volume are pivotal in a better management of HF but unless the interventions extend to an improvement in the renal function, the chances of reducing all-cause mortality seems modest. Therefore, future directions of interventions must not only be directed at close monitoring of pressures and volume simultaneously in HF patients but also at improving renal function. Moreover, it is clear that venous congestion plays a detrimental role in the deterioration of renal function and until measures are in place to reduce it, all-cause mortality will not decrease.
International Journal of Heart Failure.2024;6(4):165-173. doi:10.36628/ijhf.2024.0048
Background and Objectives:
Few studies have addressed the predictive implications of right ventricular (RV) and pulmonary arterial (PA) coupling as assessed by echocardiography in patients with acute heart failure (AHF). This study aimed to ascertain the prognostic importance of RV-PA coupling in AHF cases and discern any divergence in its prognostic efficacy based on different heart failure (HF) phenotypes.
Methods:
We evaluated RV-PA coupling by measuring the ratio of right ventricular global longitudinal strain (RVGLS) to pulmonary arterial systolic pressure (PASP), termed the RVGLS/PASP ratio, and assessed its prognostic role using the STrain for Risk Assessment and Therapeutic Strategies in Patients with Acute Heart Failure registry.
Results:
From an AHF registry of 4312 patients, we analyzed the RVGLS/PASP ratio in 2,865 patients (1,449 men; age, 71.1±13.5 years). At a median follow-up of 35.0 months, 1,199 (41.8%) patients died. Remarkably, PASP (hazard ratio [HR], 1.012; p<0.001), RVGLS (HR, 1.019;p<0.001), and the RVGLS/PASP ratio (HR, 2.426; p<0.001) were statistically significant predictors of all-cause mortality in the univariate analysis. The RVGLS/PASP ratio was a significant predictor of all-cause mortality in all the HF phenotypes, including HF with reduced ejection fraction (HR, 2.124; p=0.002), HF with mildly reduced ejection fraction (HR, 2.733; p=0.021), and HF with preserved ejection fraction (HR, 2.134; p=0.006). Multivariate analysis after adjusting for clinical and echocardiographic variables revealed that the RVGLS/PASP ratio ≤0.32 was associated with a 36% increase in all-cause mortality (HR, 1.365; p<0.001).
Conclusions
Impaired RV-PA coupling, defined as an RVGLS/PASP ratio (≤0.32) was associated with an increased risk of mortality in patients with AHF across all HF phenotypes.
Global Innovations in the Care of Patients With Heart Failure
International Journal of Heart Failure.2025;7(2):47-57. doi:10.36628/ijhf.2024.0062
The prevalence of heart failure (HF) is increasing in many regions of the world, particularly within the context of aging populations in many countries. The Heart Failure Society of America (HFSA) sought to explore areas of global HF innovation with the goal of exchanging ideas and best practices internationally. The HFSA Annual Scientific Meeting included roundtable discussions focused on the challenges faced by each of the participating regions and sharing innovative solutions. Themes identified include the lack of high-quality region-specific HF registry data that is required to accurately define patient needs and to facilitate outcome metrics; the tension between providing care that is accessible to the patient vs. concentrating highly-specialized care within tertiary centers; the need to accredit and coordinate HF care across a spectrum of healthcare delivery centers within regions; opportunities to improve the prevention and timely diagnosis of HF to enhance population outcomes, especially in communities facing healthcare disparities; and the evolution of multidisciplinary team-based care, particularly in optimizing access to guideline-directed medical therapies. This article summarizes the major themes that emerged during the roundtable sessions.
International Journal of Heart Failure.2025;7(2):121-124. doi:10.36628/ijhf.2024.0057
International Journal of Heart Failure.2025;7(2):96-97. doi:10.36628/ijhf.2025.0031
Country
Republic of Korea
Publisher
ElectronicLinks
https://e-heartfailure.org/Editor-in-chief
e-heartfailure@kshf.or.kr
Abbreviation
Int J Heart Fail
Vernacular Journal Title
ISSN
2636-154X
EISSN
2636-1558
Year Approved
2024
Current Indexing Status
Currently Indexed
Start Year
2019
Description
Power by IMICAMS (
备案号: 11010502037788, 京ICP备10218182号-8)